Heron Therapeutics

Heron Therapeutics is one of the...

• Russell 3000.

Heron Therapeutics is a company listed under the stock ticker HRTX (US).

Acquisition, funding and merger involving Heron Therapeutics.

• Heron Therapeutics has just announced a $77 Million fundraising (posted on August 11 2022).

View the org chart displaying its 17 main executives

Most searched biographies at Heron Therapeutics

• Craig Collard, Director and Chief Executive Officer
• Christian Waage, Director
• Adam Morgan, Director

Popular executive movements at Heron Therapeutics

• Kevin Kotler, Director, will leave the company on Dec. 31, 2023  (posted on December 25 2023).

Create your alert
to follow the executive moves at Heron Therapeutics.

Heron Therapeutics has 2,282 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
• Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
• Histogen has filed for bankruptcy protection  (posted on April 19 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion
• Vik Bajaj - Director at Interline Therapeutics

Learn more about the Biotechnology industry >

Press releases by Heron Therapeutics

• Heron Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022 - Heron Therapeutics
• Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability - Heron Therapeutics
• News Releases - Heron Therapeutics
• News Releases - Heron Therapeutics
• Heron Therapeutics Announces Publication Showing ZYNRELEF® as the Foundation of a Perioperative Non-Opioid Multimodal Analgesic Regimen Reduced Severe Pain and Opioid Use in Patients Undergoing Total Knee Arthroplasty - Heron Therapeutics
• Heron Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference - Heron Therapeutics
• Heron Therapeutics Presents ZYNRELEF® Data at the Society for Obstetric Anesthesia and Perinatology 54th Annual Meeting - Heron Therapeutics
• Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Recent Corporate Updates - Heron Therapeutics
• Heron Therapeutics to Report First Quarter 2022 Financial Results on Monday, May 9, 2022 - Heron Therapeutics
• Heron Therapeutics Receives European Commission Authorization for ZYNRELEF™ (HTX-011) for the Treatment of Postoperative Pain | Heron Therapeutics
• View more press releases Close

Social media about Heron Therapeutics

• Heron Therapeutics on Wikipedia, Google News & Yahoo Finance
• Heron Therapeutics on LinkedIn, Twitter & YouTube

Contact by email its executives including Craig Collard

Call Heron Therapeutics at +1 650...

View the org chart

Register to receive your alert

Report an error